RHHBY Roche Holdings Ltd AG (QX)

   By Stephen Nakrosis 
 

Genentech on Monday said the U.S. Food and Drug Administration approved its Tecentriq to treat certain patients with metastatic non-small cell lung cancer.

The company said the approval of Tecentriq, or atezolizumab, was based on an interim analysis of its Phase III IMpower110 study "showing Tecentriq demonstrated a significant overall survival benefit in people with high PD-L1 expression compared with chemotherapy."

Genentech also said the latest approval was "Tecentriq's fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall."

Tecentriq is the only single-agent cancer immunotherapy with three dosing options, Genentech said.

The company "has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies across lung, genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines," it said.

Genentech is a member of the Roche Group.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

May 18, 2020 16:17 ET (20:17 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.